Below are the most recent publications written about "fms-Like Tyrosine Kinase 3" by people in Profiles.
-
Gyan E, Minden MD, Kubo K, Rambaldi A, Juliusson G, J?dersten M, Kelly RJ, Szerafin L, He W, Gill SC, Hill JE, Chen C, Delgado D, Hasabou N. Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study. Cancer. 2025 Feb 15; 131(4):e35746.
-
Tarlock K, Gerbing RB, Ries RE, Smith JL, Leonti A, Huang BJ, Kirkey D, Robinson L, Peplinski JH, Lange B, Cooper TM, Gamis AS, Kolb EA, Aplenc R, Pollard JA, Alonzo TA, Meshinchi S. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Blood Adv. 2024 05 14; 8(9):2094-2103.
-
Cooper TM, Alonzo TA, Tasian SK, Kutny MA, Hitzler J, Pollard JA, Aplenc R, Meshinchi S, Kolb EA. Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30584.
-
Matsukawa T, Yin M, Nigam N, Negi V, Li L, Small D, Zhu YJ, Walker RL, Meltzer PS, Aplan PD. NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia. Leukemia. 2023 07; 37(7):1545-1548.
-
Meyer SE. Context is key for FLT3-ITD. Blood. 2023 03 23; 141(12):1373-1374.
-
Pollard JA, Alonzo TA, Gerbing R, Brown P, Fox E, Choi J, Fisher B, Hirsch B, Kahwash S, Getz K, Levine J, Brodersen LE, Loken MR, Raimondi S, Tarlock K, Wood A, Sung L, Kolb EA, Gamis A, Meshinchi S, Aplenc R. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. J Clin Oncol. 2022 06 20; 40(18):2023-2035.
-
Kim RS, Yaghy A, Wilde LR, Shields CL. An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor. JAMA Ophthalmol. 2020 04 01; 138(4):418-419.
-
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
-
Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, Liu C, Xie Z, Carson AR, McClain V, Stenzel TT, Miller JE. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018 04 24; 2(8):825-831.
-
Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation. Clin Cancer Res. 2018 01 01; 24(1):234-247.